Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 2/2013

01-02-2013 | Article

Common variant in the HMGA2 gene increases susceptibility to nephropathy in patients with type 2 diabetes

Authors: S. Alkayyali, M. Lajer, H. Deshmukh, E. Ahlqvist, H. Colhoun, B. Isomaa, P. Rossing, L. Groop, V. Lyssenko

Published in: Diabetologia | Issue 2/2013

Login to get access

Abstract

Aims/hypothesis

Type 2 diabetes is a chronic metabolic disorder associated with devastating microvascular complications. Genome-wide association studies have identified more than 60 genetic variants associated with type 2 diabetes and/or glucose and insulin traits, but their role in the progression of diabetes is not established. The aim of this study was to explore whether these variants were also associated with the development of nephropathy in patients with type 2 diabetes.

Methods

We studied 28 genetic variants in 2,229 patients with type 2 diabetes from the local Malmö Scania Diabetes Registry (SDR) published during 2007–2010. Diabetic nephropathy (DN) was defined as micro- or macroalbuminuria and/or end-stage renal disease. Estimated glomerular filtration rate (eGFR) was assessed using the MDRD-4 formula. Replication genotyping of rs1531343 was performed in diabetic (Steno type 2 diabetes [n = 345], Genetics of Diabetes Audit and Research in Tayside Scotland [Go-DARTS] [n = 784]) and non-diabetic (Malmö Preventive Project [n = 2,523], Botnia study [n = 2,247]) cohorts.

Results

In the SDR, HMGA2 single-nucleotide polymorphism rs1531343 was associated with DN (OR 1.50, 95% CI 1.20, 1.87, p = 0.00035). In the combined analysis totalling 3,358 patients with type 2 diabetes (n = 1,233 cases, n = 2,125 controls), carriers of the C-allele had a 1.45-fold increased risk of developing nephropathy (95% CI 1.20, 1.75, p = 0.00010). Furthermore, the risk C-allele was associated with lower eGFR in patients with type 2 diabetes (n = 2,499, β ± SEM, −3.7 ± 1.2 ml/min, p = 0.002) and also in non-diabetic individuals (n = 17,602, β ± SEM, −0.008 ± 0.003 ml/min (log e ), p = 0.006).

Conclusions/interpretation

These data demonstrate that the HMGA2 variant seems to be associated with increased risk of developing nephropathy in patients with type 2 diabetes and lower eGFR in both diabetic and non-diabetic individuals and could thus be a common denominator in the pathogenesis of type 2 diabetes and kidney complications.
Appendix
Available only for authorised users
Literature
1.
Chin MT, Pellacani A, Wang H et al (1998) Enhancement of serum-response factor-dependent transcription and DNA binding by the architectural transcription factor HMG-I(Y). J Biol Chem 273:9755–9760PubMedCrossRef
2.
Forbes JM, Fukami K, Cooper ME (2007) Diabetic nephropathy: where hemodynamics meets metabolism. Exp Clin Endocrinol Diabetes 115:69–84PubMedCrossRef
3.
4.
Harris MI, Flegal KM, Cowie CC et al (1998) Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988–1994. Diabetes Care 21:518–524PubMedCrossRef
5.
Di Landro D, Catalano C, Lambertini D et al (1998) The effect of metabolic control on development and progression of diabetic nephropathy. Nephrol Dial Transplant 13(Suppl 8):35–43PubMedCrossRef
6.
The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977–986
7.
UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837–853
8.
Valmadrid CT, Klein R, Moss SE, Klein BE (2000) The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 160:1093–1100PubMedCrossRef
9.
Fioretto P, Mauer M, Brocco E et al (1996) Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 39:1569–1576PubMedCrossRef
10.
Stevens LA, Coresh J, Greene T, Levey AS (2006) Assessing kidney function—measured and estimated glomerular filtration rate. N Engl J Med 354:2473–2483PubMedCrossRef
11.
Harjutsalo V, Katoh S, Sarti C, Tajima N, Tuomilehto J (2004) Population-based assessment of familial clustering of diabetic nephropathy in type 1 diabetes. Diabetes 53:2449–2454PubMedCrossRef
12.
Billings LK, Florez JC (2010) The genetics of type 2 diabetes: what have we learned from GWAS? Ann N Y Acad Sci 1212:59–77PubMedCrossRef
13.
Lindholm E, Agardh E, Tuomi T, Groop L, Agardh CD (2001) Classifying diabetes according to the new WHO clinical stages. Eur J Epidemiol 17:983–989PubMedCrossRef
14.
Ahluwalia TS, Lindholm E, Groop LC (2011) Common variants in CNDP1 and CNDP2, and risk of nephropathy in type 2 diabetes. Diabetologia 54:2295–2302PubMedCrossRef
15.
Alkhalaf A, Zurbig P, Bakker SJ et al (2010) Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy. PLoS One 5:e13421PubMedCrossRef
16.
National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39: S1-266
17.
Wong TY, Choi PC, Szeto CC et al (2002) Renal outcome in type 2 diabetic patients with or without coexisting nondiabetic nephropathies. Diabetes Care 25:900–905PubMedCrossRef
18.
Morris AD, Boyle DI, MacAlpine R et al (1997) The diabetes audit and research in Tayside Scotland (DARTS) study: electronic record linkage to create a diabetes register. DARTS/MEMO Collaboration. BMJ 315:524–528PubMedCrossRef
19.
Peterson B, Trell E, Kristenson H (1983) Comparison of gamma-glutamyltransferase and questionnaire test as alcohol indicators in different risk groups. Drug Alcohol Depend 11:279–286PubMedCrossRef
20.
Berglund G, Nilsson P, Eriksson KF et al (2000) Long-term outcome of the Malmo preventive project: mortality and cardiovascular morbidity. J Intern Med 247:19–29PubMedCrossRef
21.
Groop L, Forsblom C, Lehtovirta M et al (1996) Metabolic consequences of a family history of NIDDM (the Botnia study): evidence for sex-specific parental effects. Diabetes 45:1585–1593PubMedCrossRef
22.
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461–470PubMed
23.
Voight BF, Scott LJ, Steinthorsdottir V et al (2010) Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 42:579–589PubMedCrossRef
24.
Dupuis J, Langenberg C, Prokopenko I et al (2010) New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 42:105–116PubMedCrossRef
25.
Saxena R, Hivert MF, Langenberg C et al (2010) Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet 42:142–148PubMedCrossRef
26.
Zeggini E, Scott LJ, Saxena R et al (2008) Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet 40:638–645PubMedCrossRef
27.
Yasuda K, Miyake K, Horikawa Y et al (2008) Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat Genet 40:1092–1097PubMedCrossRef
28.
Kottgen A, Pattaro C, Boger CA et al (2010) New loci associated with kidney function and chronic kidney disease. Nat Genet 42:376–384PubMedCrossRef
29.
McDonough CW, Palmer ND, Hicks PJ et al (2011) A genome-wide association study for diabetic nephropathy genes in African Americans. Kidney Int 79:563–572PubMedCrossRef
30.
Bianchi ME, Agresti A (2005) HMG proteins: dynamic players in gene regulation and differentiation. Curr Opin Genet Dev 15:496–506PubMedCrossRef
31.
Reeves R, Beckerbauer L (2001) HMGI/Y proteins: flexible regulators of transcription and chromatin structure. Biochim Biophys Acta 1519:13–29PubMedCrossRef
32.
Li O, Vasudevan D, Davey CA, Droge P (2006) High-level expression of DNA architectural factor HMGA2 and its association with nucleosomes in human embryonic stem cells. Genesis 44:523–529PubMedCrossRef
33.
34.
Persson F, Andren Y, Winnes M et al (2009) High-resolution genomic profiling of adenomas and carcinomas of the salivary glands reveals amplification, rearrangement, and fusion of HMGA2. Gene Chromosome Canc 48:69–82CrossRef
35.
Fedele M, Battista S, Kenyon L et al (2002) Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene 21:3190–3198PubMedCrossRef
36.
Thuault S, Valcourt U, Petersen M, Manfioletti G, Heldin CH, Moustakas A (2006) Transforming growth factor-beta employs HMGA2 to elicit epithelial-mesenchymal transition. J Cell Biol 174:175–183PubMedCrossRef
Metadata
Title
Common variant in the HMGA2 gene increases susceptibility to nephropathy in patients with type 2 diabetes
Authors
S. Alkayyali
M. Lajer
H. Deshmukh
E. Ahlqvist
H. Colhoun
B. Isomaa
P. Rossing
L. Groop
V. Lyssenko
Publication date
01-02-2013
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 2/2013
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-012-2760-5

Other articles of this Issue 2/2013

Diabetologia 2/2013 Go to the issue

Article

Small-molecule inhibitors of the cystic fibrosis transmembrane conductance regulator increase pancreatic endocrine cell development in rat and mouse

Commentary

Lipotoxicity impairs incretin signalling

Article

Identification of the antibiotic ionomycin as an unexpected peroxisome proliferator-activated receptor γ (PPARγ) ligand with a unique binding mode and effective glucose-lowering activity in a mouse model of diabetes

Article

Exome sequencing-driven discovery of coding polymorphisms associated with common metabolic phenotypes

Article

Syntaxin-3 regulates newcomer insulin granule exocytosis and compound fusion in pancreatic beta cells

Article

cAMP response element binding protein H mediates fenofibrate-induced suppression of hepatic lipogenesis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits